Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 0 · 0%Moderate 1 · 50%High 0 · 0%

Rituximab vs other disease‐modifying treatments

Interferons or glatiramer acetate · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes interferons or glatiramer acetate compared with other disease‐modifying treatments (very low certainty).

1 finding from 1 review

Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
HR 0.86 [0.52, 1.42]
853 participants
Very low

Rituximab vs other disease‐modifying treatments

Interferon beta or glatiramer acetate · relapsing multiple sclerosis

Rituximab as 'switching' probably leads to higher interferon beta or glatiramer acetate compared with other disease‐modifying treatments (moderate certainty).

1 finding from 1 review

Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
OR 1.71 [1.11, 2.62]
5477 participants
Moderate